A highly durable RNAi therapeutic inhibitor of PCSK9

Cited by (775)

Items 101–200 of 775

1. From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases
   Ulf Landmesser, Wolfgang C. Poller, Sotirios Tsimikas, Patrick Most, Francesco Paneni, Thomas Felix Lüscher · 2020 · European Heart Journal
2. Inclisiran: a new promising agent in the management of hypercholesterolemia
   Kosmas, Constantine E., Muñoz Estrella, Alba, Sourlas, Andreas, Silverio, Delia, Hilario, Elizabeth, Montan, Peter D., Guzman, Eliscer · 2018 · Diseases
3. Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias
   Katzmann, Julius L., Packard, Chris J., Chapman, M. John, Katzmann, Isabell, Laufs, Ulrich · 2020 · Journal of the American College of Cardiology
4. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia
   Khan, Sajjad A., Naz, Arshi, Qamar Masood, Muhammad, Shah, Rahman · 2020 · The American Journal of Cardiology
5. An Update: Enzymatic Synthesis for Industrial Applications
   Thomas Bayer, Shuke Wu, Radka Šnajdrová, Kai Baldenius, Uwe T. Bornscheuer · 2025 · Angewandte Chemie International Edition
6. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo
   Nidhi Jyotsana, Amit Kumar Sharma, Anuhar Chaturvedi, Ramachandramouli Budida, Michaela Scherr, Florian C. Kuchenbauer, Robert M. Lindner, Fatih Noyan, Kurt‐Wolfram Sühs, Martin Stangel et al. · 2019 · Annals of Hematology
7. Reversal of siRNA-mediated gene silencing in vivo
   Ivan Zlatev, Adam B. Castoreno, Christopher R. Brown, June Qin, Scott Waldron, Mark K. Schlegel, Rohan Degaonkar, Svetlana Shulga‐Morskaya, Huilei Xu, Swati Gupta et al. · 2018 · Nature Biotechnology
8. Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association
   Larry B. Goldstein, Peter Paul Toth, Jennifer L. Dearborn, Robert Patrick Giugliano, Benjamin J. Hirsh, Jessica M. Peña, Magdy H. Selim, Daniel Woo · 2023 · Arteriosclerosis Thrombosis and Vascular Biology
9. A new dawn for managing dyslipidemias: The era of rna-based therapies
   Chiara Macchi, Cesare Riccardo Sirtori, Alberto Corsini, Raul Dias Santos, Gerald Francis Watts, Massimiliano Ruscica · 2019 · Pharmacological Research
10. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders
    O’Connell, Emma M., Lohoff, Falk W. · 2020 · Frontiers in Neuroscience
11. Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease
    Simon Glerup, Rainer Schulz, Ulrich Laufs, Klaus‐Dieter Schlüter · 2017 · Basic Research in Cardiology
12. Endocytosis of lipoproteins
    Paolo Zanoni, Srividya Velagapudi, Mustafa Yalçınkaya, Lucia Rohrer, Arnold von Eckardstein · 2018 · Atherosclerosis
13. In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model
    Alba Carreras, Luna Simona Pane, Roberto Nitsch, Katja Madeyski-Bengtson, Michelle J. Porritt, Pınar Akçakaya, Amir Taheri‐Ghahfarokhi, Elke Ericson, Mikael Bjursell, Marta Pérez-Alcázar et al. · 2019 · BMC Biology
14. Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation
    Angelos D. Karagiannis, Martin Liu, Peter Paul Toth, Shijia Zhao, Devendra K. Agrawal, Peter Libby, Yiannis S. Chatzizisis · 2018 · Current Atherosclerosis Reports
15. Chirality matters: stereo-defined phosphorothioate linkages at the termini of small interfering RNAs improve pharmacology in vivo
    Hartmut Jahns, Nate Taneja, Jennifer L. S. Willoughby, Masaaki Akabane‐Nakata, Christopher R. Brown, Tuyen M Nguyen, Anna Bisbe, Shigeo Matsuda, Matt Hettinger, Rajar M. Manoharan et al. · 2021 · Nucleic Acids Research
16. Chirality Dependent Potency Enhancement and Structural Impact of Glycol Nucleic Acid Modification on siRNA
    Mark K. Schlegel, Donald J. Foster, Alexander V. Kel’in, Ivan Zlatev, Anna Bisbe, Muthusamy Jayaraman, Jeremy G. Lackey, Kallanthottathil G. Rajeev, Klaus Charissé, Joel M. Harp et al. · 2017 · Journal of the American Chemical Society
17. Regulation of angiogenesis by microRNAs in cardiovascular diseases
    Devika Kir, Erica K. Schnettler, Shrey Modi, Sundaram Ramakrishnan · 2018 · Angiogenesis
18. RNA Therapeutics in Cardiovascular Precision Medicine
    Ageliki Laina, Aikaterini Gatsiou, Georgios A. Georgiopoulos, Kimon S. Stamatelopoulos, Konstantinos Stellos · 2018 · Frontiers in Physiology
19. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies
    Nabil Georges Seidah, Annik Prat, Angela Pirillo, Alberico Luigi Catapano, Giuseppe Danilo Norata · 2019 · Cardiovascular Research
20. RNA Therapy: Current Status and Future Potential
    Young‐Kook Kim · 2020 · Chonnam Medical Journal
21. PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction
    Hua Ling Sun, Ronald M. Krauss, Jeffrey T. Chang, Ba‐Bie Teng · 2017 · Journal of Lipid Research
22. Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review
    Merćep, Iveta, Friščić, Nikolina, Strikić, Dominik, Reiner, Željko · 2022 · Cardiovascular Therapeutics
23. Pharmacokinetics and Pharmacodynamics of GalNAc‐Conjugated siRNAs
    Guohua An · 2023 · The Journal of Clinical Pharmacology
24. Small molecules as inhibitors of PCSK9: Current status and future challenges
    Xu, Shengtao, Luo, Shanshan, Zhu, Zheying, Xu, Jinyi · 2019 · European Journal of Medicinal Chemistry
25. Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies
    Arturo Cesaro, Alessandra Schiavo, Elisabetta Moscarella, Silvio Coletta, Matteo Conte, Felice Gragnano, Fabio Fimiani, Emanuele Monda, Martina Caiazza, Giuseppe Limongelli et al. · 2020 · Journal of Cardiovascular Medicine
26. Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials
    R. Scott Wright, Wolfgang Köenig, Ulf Landmesser, Lawrence A. Leiter, Frederick Johan Raal, Gregory G. Schwartz, Anastasia Lesogor, Pierre Maheux, Christian Stratz, Xiao Zang et al. · 2023 · Journal of the American College of Cardiology
27. Safe and effective in vivo delivery of DNA and RNA using proteolipid vehicles
    Douglas W. Brown, Ping Wee, Prakash Bhandari, Amirali B. Bukhari, Liliya Grin, Héctor Vega, Maryam Hejazi, Deborah L. Sosnowski, Jailal Ablack, Eileen K. Clancy et al. · 2024 · Cell
28. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1
    Landmesser, Ulf, Haghikia, Arash, Leiter, Lawrence A, Wright, R Scott, Kallend, David, Wijngaard, Peter, Stoekenbroek, Robert, Kastelein, John Jp, Ray, Kausik K · 2021 · Cardiovascular Research
29. Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights
    Stein, Ricardo, Ferrari, Filipe, Scolari, Fernando · 2019 · Current Cardiology Reports
30. Methylomic profiling and replication implicates deregulation of PCSK9 in alcohol use disorder
    Falk W. Lohoff, Jill L. Sorcher, Allison D. Rosen, Kelsey L. Mauro, R R Fanelli, Reza Momenan, Colin A. Hodgkinson, Leandro Franco Vendruscolo, George F. Koob, Melanie L. Schwandt et al. · 2017 · Molecular Psychiatry
31. The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies
    Maja M. Janas, Carole E. Harbison, Victoria Kristina Perry, Brenda A. Carito, Jessica E. Sutherland, Akshay K. Vaishnaw, Natalie D. Keirstead, Garvin L. Warner · 2018 · Toxicologic Pathology
32. Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates
    Maja M. Janas, Ivan Zlatev, Ju Liu, Yongfeng Jiang, Scott A. Barros, Jessica E. Sutherland, Wendell P. Davis, Jingxuan Liu, Christopher R. Brown, Xiumin Liu et al. · 2019 · Nucleic Acids Research
33. American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia.
    Shailendra B. Patel, Kathleen L. Wyne, Samina Afreen, L. Belalcazar, Melanie D. Bird, Sarah Coles, J. Marrs, C. Peng, Vishnu Priya Pulipati, Shahnaz Sultan et al. · 2025 · Endocrine Practice
34. Lomitapide for the treatment of hypercholesterolemia
    Amanda J. Berberich, Robert Alexander Hegele · 2017 · Expert Opinion on Pharmacotherapy
35. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents
    Chiara Macchi, Maciej Banach, Alberto Corsini, CR Sirtori, Nicola Ferri, Massimiliano Ruscica · 2019 · European Journal of Preventive Cardiology
36. Challenges and Opportunities for Nucleic Acid Therapeutics
    David R. Corey, Masad José Damha, Muthiah Manoharan · 2021 · Nucleic Acid Therapeutics
37. siRNA therapeutics and its challenges: Recent advances in effective delivery for cancer therapy
    Arpita Paul, Anuraag Muralidharan, Avirup Biswas, B. Venkatesh Kamath, Alex Joseph, Angel Treasa Alex · 2022 · OpenNano
38. Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial
    Frederick Johan Raal, Nyda Fourie, Russell S. Scott, Dirk Jacobus Blom, Matthys De Vries Basson, Meral Kayıkçıoğlu, Kate Caldwell, David G. Kallend, Evan A. Stein, LIBerate-HeFH Investigators et al. · 2023 · European Heart Journal
39. Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles
    Annabelle Biscans, Jillian Caiazzi, Nicholas McHugh, Vignesh Narayan Hariharan, Manish Muhuri, Anastasia Khvorova · 2020 · Molecular Therapy
40. The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer
    Nabil Georges Seidah · 2021 · Journal of Lipid Research
41. Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
    Niki Katsiki, Michal Vrablı́k, Maciej Banach, Ioanna Gouni‐Berthold · 2023 · Pharmaceuticals
42. siRNA Therapeutics against Respiratory Viral Infections—What Have We Learned for Potential COVID‐19 Therapies?
    Aditi Mehta, Thomas Michler, Olivia M. Merkel · 2021 · Advanced Healthcare Materials
43. Role of PCSK9 in lipid metabolism and atherosclerosis
    Xiaolong Lin, Lele Xiao, Zhi‐Han Tang, Zhi‐Sheng Jiang, Mi‐Hua Liu · 2018 · Biomedicine & Pharmacotherapy
44. Nanoparticles-Based Strategies to Improve the Delivery of Therapeutic Small Interfering RNA in Precision Oncology
    Jinxing Huang, Kai Xiao · 2022 · Pharmaceutics
45. Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists
    Yingnan Zhang, Mark H. Ultsch, Nicholas J. Skelton, Daniel J. Burdick, Maureen H. Beresini, Wei Li, Monica Kong-Beltran, Andrew S. Peterson, John G. Quinn, Cecilia Chiu et al. · 2017 · Nature Structural & Molecular Biology
46. Non-viral nanoparticles for RNA interference: Principles of design and practical guidelines
    Zehua Liu, Shiqi Wang, Christos Tapeinos, Giulia Torrieri, Voitto Känkänen, Nesma El‐Sayed, André Python, Jouni J. Hirvonen, Hélder A. Santos · 2021 · Advanced Drug Delivery Reviews
47. RNA Therapeutics for the Cardiovascular System
    Victor J. Dzau, Conrad P. Hodgkinson · 2024 · Circulation
48. Liver-Targeted Anti-HBV Single-Stranded Oligonucleotides with Locked Nucleic Acid Potently Reduce HBV Gene Expression In Vivo
    Hassan Javanbakht, Henrik Mueller, Johanna Walther, Xue Zhou, Anaïs Lopez, Thushara Pattupara, Julie Blaising, Lykke Pedersen, Nanna Albæk, Malene Jackerott et al. · 2018 · Molecular Therapy — Nucleic Acids
49. Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
    Chandni Bardolia, Nishita Shah Amin, Jacques Turgeon · 2021 · Frontiers in Cardiovascular Medicine
50. The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and efficacy
    Annabelle Biscans, Jillian Caiazzi, Sarah M. Davis, Nicholas McHugh, Jacquelyn Sousa, Anastasia Khvorova · 2020 · Nucleic Acids Research
51. Advances in biological therapies for dyslipidemias and atherosclerosis
    Eftaxia-Konstantina Valanti, Katerina Dalakoura-Karagkouni, Gerasimos Siasos, Dimitris Kardassis, Aristides G. Eliopoulos, Despina Sanoudou · 2020 · Metabolism
52. Recent advances on nanoparticle-based therapies for cardiovascular diseases
    Rema Sreenivasan Soumya, Kozhiparambil Gopalan Raghu · 2022 · Journal of Cardiology
53. First Report of siRNA Uptake (for RNA Interference) During Ex Vivo Hypothermic and Normothermic Liver Machine Perfusion
    Andrew R. Gillooly, Jessica Perry, Paulo Ney Aguiar Martins · 2018 · Transplantation
54. Therapeutic modulation of the bile acid pool by Cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice
    Raphaël Chèvre, Laia Trigueros‐Motos, David Castaño, Tricia Chua, Maria Corlianò, Jay V. Patankar, Lareina Sng, Lauren Sim, Tan Liang Juin, Guillaume Carissimo et al. · 2018 · The FASEB Journal
55. Lipid lowering agents of natural origin: An account of some promising chemotypes
    Suriya P. Singh, Koneni V. Sashidhara · 2017 · European Journal of Medicinal Chemistry
56. Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review
    Bimmer E.P.M. Claessen, Paul Guedeney, Charles Michael Gibson, Dominick Joseph Angiolillo, Davide Cao, Norman E. Lepor, Roxana Mehran · 2020 · Journal of the American Heart Association
57. The Long Non-Coding RNA HOTAIR Is a Critical Epigenetic Mediator of Angiogenesis in Diabetic Retinopathy
    Saumik Biswas, Biao Feng, Shali Chen, Jieting Liu, Erfan Aref‐Eshghi, John R. Gonder, Vy Ngo, Bekim Sadiković, Subrata Chakrabarti · 2021 · Investigative Ophthalmology & Visual Science
58. Epsin Nanotherapy Regulates Cholesterol Transport to Fortify Atheroma Regression
    Kui Cui, Xinlei Gao, Beibei Wang, Hao Wu, Arulsamy Kulandaisamy, Yunzhou Dong, Yuling Xiao, Xingya Jiang, Marina V. Malovichko, Kathryn S. Li et al. · 2022 · Circulation Research
59. Oxidized low-density lipoprotein (oxLDL) affects load-free cell shortening of cardiomyocytes in a proprotein convertase subtilisin/kexin 9 (PCSK9)-dependent way
    Klaus‐Dieter Schlüter, Annemarie Wolf, Martin Weber, Rolf Schreckenberg, Rainer Schulz · 2017 · Basic Research in Cardiology
60. Long Noncoding RNAs in Atherosclerosis and Vascular Injury
    Jacob B. Pierce, Mark W. Feinberg · 2020 · Arteriosclerosis Thrombosis and Vascular Biology
61. PCSK9 targets important for lipid metabolism
    Rainer Schulz, Klaus‐Dieter Schlüter · 2017 · Clinical Research in Cardiology Supplements
62. Advances in Pathophysiology of Calcific Aortic Valve Disease Propose Novel Molecular Therapeutic Targets
    Alexia Hulin, Alexandre Hego, Patrizio Lancellotti, Cécile Oury · 2018 · Frontiers in Cardiovascular Medicine
63. Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors
    Ivan Pećin, Merel L. Hartgers, G. Kees Hovingh, Ricardo E. Dent, Željko Reiner · 2017 · European Journal of Preventive Cardiology
64. Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development
    Shalini Andersson, Madeleine Antonsson, Marie Elebring, Rasmus Jansson‐Löfmark, Lars O. G. Weidolf · 2018 · Drug Discovery Today
65. Current progress of research on intestinal bacterial translocation
    Yanhua Wang · 2020 · Microbial Pathogenesis
66. Gene Silencing With siRNA (RNA Interference): A New Therapeutic Option During Ex Vivo Machine Liver Perfusion Preservation
    Max F. Thijssen, Isabel M.A. Brüggenwirth, Andrew R. Gillooly, Anastasia Khvorova, Timothy F. Kowalik, Paulo Ney Aguiar Martins · 2018 · Liver Transplantation
67. Inclisiran: a novel agent for lowering apolipoprotein B–containing lipoproteins
    Warden, Bruce A., Duell, Paul Barton · 2021 · Journal of Cardiovascular Pharmacology
68. Nanomedicine Approaches for Advanced Diagnosis and Treatment of Atherosclerosis and Related Ischemic Diseases
    Bin Hu, Kofi Oti Boakye‐Yiadom, Wei Yu, Zi‐Wei Yuan, William Ho, Xiaoyang Xu, Xue‐Qing Zhang · 2020 · Advanced Healthcare Materials
69. New Pharmacological Approaches to Target PCSK9
    Alberico Luigi Catapano, Angela Pirillo, Giuseppe Danilo Norata · 2020 · Current Atherosclerosis Reports
70. Lipid lowering therapy in cardiovascular disease: From myth to molecular reality
    Philipp Mourikis, Saif Zako, Lisa Dannenberg, Amir M. Nia, Yvonne Heinen, Lucas Busch, Hannah Richter, Thomas Hohlfeld, Tobias Zeus, Malte Kelm et al. · 2020 · Pharmacology & Therapeutics
71. New Therapies for Primary Hyperlipidemia
    Carlos Alberto Aguilar-Salinas, Rita Angélica Gómez-Díaz, Pablo Corral · 2021 · The Journal of Clinical Endocrinology & Metabolism
72. Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9
    Lili Wang, Camilo Ayala Breton, Claude C. Warzecha, Peter L. Bell, Hanying Yan, Zhenning He, John White, Yanqing Zhu, Mingyao Li, Elizabeth L. Buza et al. · 2021 · Molecular Therapy
73. Targeted Strategy in Lipid-Lowering Therapy
    Ezgi Dayar, Oľga Pecháňová · 2022 · Biomedicines
74. Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias
    Clarice Gareri, Alberto Polimeni, Salvatore A. Giordano, Laura Tammè, Antonio Curcio, Ciro Indolfi · 2022 · Journal of Clinical Medicine
75. Inclisiran: a new generation of lipid-lowering siRNA therapeutic
    Yanzhen Zhang, Huaigang Chen, Lang Hong, Hong Wang, Bin Li, Mengyin Zhang, Jiamei Li, Yang Liu, Fan Liu · 2023 · Frontiers in Pharmacology
76. Enhancing siRNA efficacy in vivo with extended nucleic acid backbones
    Ken Yamada, Vignesh Narayan Hariharan, Jillian Caiazzi, Rachael Miller, Chantal M. Ferguson, Ellen Sapp, Hassan H. Fakih, Qi Tang, Nozomi Yamada, Raymond C. Furgal et al. · 2024 · Nature Biotechnology
77. Therapeutic RNA-silencing oligonucleotides in metabolic diseases
    Goga, Algera, Stoffel, Markus · 2022 · Nature Reviews Drug Discovery
78. ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases
    Fei Luo, Avash Das, Sumeet A. Khetarpal, Zhenfei Fang, Thomas A. Zelniker, Robert S. Rosenson, Arman Qamar · 2023 · Trends in Cardiovascular Medicine
79. RIPK1 gene variants associate with obesity in humans and can be therapeutically silenced to reduce obesity in mice
    Denuja Karunakaran, Adam W. Turner, Anne‐Claire Duchez, Sébastien Soubeyrand, Adil Rasheed, David R. Smyth, David P. Cook, Majid Nikpay, Joshua W. Kandiah, Calvin Pan et al. · 2020 · Nature Metabolism
80. 25 years of maturation: A systematic review of RNAi in the clinic
    Ida Juhl Corydon, Bjørn K. Fabian-Jessing, Thomas Stax Jakobsen, Asbjørn Cortnum Jørgensen, Emilie Grarup Jensen, Anne Louise Askou, Lars Aagaard, Thomas J. Corydon · 2023 · Molecular Therapy — Nucleic Acids
81. Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria
    Tracy L. McGregor, Karen A. Hunt, Elaine Yee, Dan Mason, Paul Nioi, Simina Ticau, Marissa Pelosi, Perry R Loken, Sarah Finer, Debbie A. Lawlor et al. · 2020 · eLife
82. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes
    Parsa Akbari, Olukayode Ayodeji Sosina, Jonas Bovijn, Karl Landheer, Jonas Bille Nielsen, Minhee Kim, Senem Aykul, Tanima De, Mary E. Haas, George Hindy et al. · 2022 · Nature Communications
83. Inclisiran for the treatment of dyslipidemia
    Toshiyuki Nishikido, Kausik Kumar Ray · 2018 · Expert Opinion on Investigational Drugs
84. Recent preclinical and clinical advances in oligonucleotide conjugates
    Kevin P. Craig, Marc T. Abrams, Mansoor M. Amiji · 2018 · Expert Opinion on Drug Delivery
85. EHRA White Paper: knowledge gaps in arrhythmia management—status 2019
    Andreas Goette, Angelo Auricchio, Giuseppe Boriani, Frieder Braunschweig, Josép Brugada, Haran Burri, A. John Camm, Harry J.G.M. Crijns, Nikolaos Dagres, Jean‐Claude Deharo et al. · 2019 · EP Europace
86. Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment
    Shakir Ahamad, Shahnawaz Ali Bhat · 2022 · Journal of Medicinal Chemistry
87. Chemical engineering of CRISPR–Cas systems for therapeutic application
    Halle M. Barber, Adrian A. Pater, Keith T. Gagnon, Masad José Damha, Daniel O’Reilly · 2024 · Nature Reviews Drug Discovery
88. A Therapeutic Silencing RNA Targeting Hepatocyte TAZ Prevents and Reverses Fibrosis in Nonalcoholic Steatohepatitis in Mice
    Xiaobo Wang, Mark R. Sommerfeld, Kerstin Jahn‐Hofmann, Bishuang Cai, Aveline A. Filliol, Helen Elaine Remotti, Robert F. Schwabe, Aimo Kannt, Ira A. Tabas · 2019 · Hepatology Communications
89. Future perspectives of the pharmacological management of diabetic dyslipidemia
    Angelo Maria Patti, Rosaria Vincenza Giglio, Νικόλαος Παπάνας, Manfredi Rizzo, Ali Abbas Rizvi · 2019 · Expert Review of Clinical Pharmacology
90. ROR2 blockade as a therapy for osteoarthritis
    Anne‐Sophie Thorup, Danielle Strachan, Sara Caxaria, B. Poulet, Bethan Lynne Thomas, Suzanne Elizabeth Eldridge, Giovanna Nalesso, James R. Whiteford, Costantino Pitzalis, Thomas G Aigner et al. · 2020 · Science Translational Medicine
91. Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
    Constantine E. Kosmas, Alba Muñoz Estrella, Andreas Skavdis, Edilberto Peña Genao, Ian Martinez, Eliscer Guzman · 2020 · Therapeutics and Clinical Risk Management
92. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia
    Banerjee, Yajnavalka, Pantea Stoian, Anca, Cicero, Arrigo Francesco Giuseppe, Fogacci, Federica, Nikolic, Dragana, Sachinidis, Alexandros, Rizvi, Ali A., Janez, Andrej, Rizzo, Manfredi · 2022 · Expert Opinion on Drug Safety
93. New Frontiers in Lp(a)-Targeted Therapies
    Matthew J. Borrelli, Amer Youssef, Michael B. Boffa, Marlys L. Koschinsky · 2019 · Trends in Pharmacological Sciences
94. Folate Receptor-Mediated siRNA Delivery: Recent Developments and Future Directions for RNAi Therapeutics
    Sumit Gangopadhyay, Rahul R. Nikam, Kiran R. Gore · 2021 · Nucleic Acid Therapeutics
95. The Long Non-coding Road to Atherosclerosis
    Tatjana Josefs, Reinier Abraham Boon · 2020 · Current Atherosclerosis Reports
96. Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics
    Thijs Van de Vyver, Stefaan C. De Smedt, Koen Raemdonck · 2021 · Advanced Drug Delivery Reviews
97. Targeting RNA with synthetic oligonucleotides: Clinical success invites new challenges
    Cristina R. Hofman, David R. Corey · 2023 · Cell chemical biology
98. Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
    Daniel Philip Judge, Arnt V. Kristen, Martha A. Grogan, Mathew S. Maurer, Rodney H. Falk, Mazen A Hanna, Julian David Gillmore, Pushkal P. Garg, Akshay K. Vaishnaw, Jamie Harrop et al. · 2020 · Cardiovascular Drugs and Therapy
99. Recent Advancements in Liposome-Targeting Strategies for the Treatment of Gliomas: A Systematic Review
    Jie Li, Tiantian Tan, Liping Zhao, Mengmeng Liu, Yu You, Yiying Zeng, Dajing Chen, Tian Xie, Lele Zhang, Chaomei Fu et al. · 2020 · ACS Applied Bio Materials
100. PCSK9 in metabolism and diseases
     Ajoolabady, Amir, Pratico, Domenico, Mazidi, Mohsen, Davies, Ian G., Lip, Gregory Y.H., Seidah, Nabil, Libby, Peter, Kroemer, Guido, Ren, Jun · 2025 · Metabolism